Document is current
Any future updates will be listed below
-
Authors
Qing, Tao
Karn, Thomas https://orcid.org/0000-0002-3264-6573
Rozenblit, Mariya
Foldi, Julia https://orcid.org/0000-0002-7504-867X
Marczyk, Michal https://orcid.org/0000-0003-2508-5736
Shan, Naing Lin https://orcid.org/0000-0002-8572-1311
Blenman, Kim https://orcid.org/0000-0001-6070-0728
Holtrich, Uwe
Kalinsky, Kevin https://orcid.org/0000-0002-3113-7902
Meric-Bernstam, Funda
Pusztai, Lajos https://orcid.org/0000-0001-9632-6686
-
Funding
Funding for this research was provided by:
Susan G. Komen (SAC160076)
Breast Cancer Research Foundation (BCRF-21-133)
- License Information
-
More Information
Article History
Received: 26 March 2022
Accepted: 26 October 2022
First Online: 7 November 2022
Competing interests
: L.P. has received consulting fees and honoraria from Pfizer, Astra Zeneca, Merck, Novartis, Bristol-Myers Squibb, Genentech, Eisai, Pieris, Immunomedics, Seattle Genetics, Clovis, Syndax, H3Bio, and Daiichi. The remaining authors declare no competing interests.
